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Abstract
The human immunodeficiency virus (HIV-1) exterior envelope glycoprotein, gp120, mediates receptor binding and is the major target
for neutralizing antibodies. Primary HIV-1 isolates are characteristically more resistant to broadly neutralizing antibodies, although the
structural basis for this resistance remains obscure. Most broadly neutralizing antibodies are directed against functionally conserved gp120
regions involved in binding to either the primary virus receptor, CD4, or the viral coreceptor molecules that normally function as chemokine
receptors. These antibodies are known as CD4 binding site (CD4BS) and CD4-induced (CD4i) antibodies, respectively. Inspection of the
gp120 crystal structure reveals that although the receptor-binding regions lack glycosylation, sugar moieties lie proximal to both
receptor-binding sites on gp120 and thus in proximity to both the CD4BS and the CD4i epitopes. In this study, guided by the X-ray crystal
structure of gp120, we deleted four N-linked glycosylation sites that flank the receptor-binding regions. We examined the effects of selected
changes on the sensitivity of two prototypic HIV-1 primary isolates to neutralization by antibodies. Surprisingly, removal of a single
N-linked glycosylation site at the base of the gp120 third variable region (V3 loop) increased the sensitivity of the primary viruses to
neutralization by CD4BS antibodies. Envelope glycoprotein oligomers on the cell surface derived from the V3 glycan-deficient virus were
better recognized by a CD4BS antibody and a V3 loop antibody than were the wild-type glycoproteins. Absence of all four glycosylation
sites rendered a primary isolate sensitive to CD4i antibody-mediated neutralization. Thus, carbohydrates that flank receptor-binding regions
on gp120 protect primary HIV-1 isolates from antibody-mediated neutralization.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
Human immunodeficiency virus type 1 (HIV-1) is the
etiologic agent of acquired immunodeficiency syndrome
(AIDS) (Barre-Sinoussi et al., 1983; Gallo et al., 1984). The
heavily glycosylated envelope glycoproteins of HIV-1, the
exterior envelope glycoprotein, gp120 (SU), and the trans-
membrane glycoprotein, gp41 (TM), are assembled in an
oligomeric spike on the virion surface (Earl et al., 1990;
Kowalski et al., 1987; Otteken et al., 1996). These glyco-
proteins are generated from a gp160 precursor glycoprotein
and, following cleavage by cellular proteases, remain non-
covalently associated on the cell or viral surface. The gp120
glycoprotein is composed of variable regions (V1–V5) and
constant regions (C1–C5) and is the major target for neu-
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tralizing antibodies. The variable loops may contribute to
evasion of host immune responses both by permitting the
existence of replication-competent viral variants able to
evade strain-restricted neutralizing antibodies and by shield-
ing more conserved envelope regions from host antibody
responses (Cao et al., 1997).
The heterotrimeric envelope glycoprotein spikes mediate
virus entry into susceptible target cells by sequential bind-
ing of gp120 to the primary viral receptor, CD4, and to
specific proteins of the chemokine receptor family, which
serve as coreceptors (Alkhatib et al., 1996; Choe et al.,
1996; Feng et al., 1996; Maddon et al., 1986). In vivo, the
two major HIV-1 coreceptors are CCR5 and CXCR4. Pri-
mary isolates of HIV-1 predominantly use the chemokine
receptor CCR5 as a coreceptor (R5 viruses); later in the
course of HIV-1 infection isolates that utilize both CCR5
and CXCR4 may appear (R5X4 viruses) (Connor et al.,
1997). Viruses that replicate under diminished immune se-
lective pressures may acquire the ability to use CXCR4
exclusively or in addition to other chemokine receptors.
Viruses that become CXCR4-dependent are referred to as T
cell tropic (X4 viruses) and include T cell line, laboratory-
adapted HIV-1 variants (TCLA viruses). TCLA viruses are
typically more sensitive to antibody neutralization than the
primary viruses from which they are derived. The mecha-
nism by which sensitivity to neutralizing ligands is acquired
is not clear and is manifest only in the context of the
functional trimeric envelope spike. For example, mono-
meric gp120 glycoproteins derived from either soluble CD4
(sCD4)-resistant primary isolates or sCD4-sensitive TCLA
viruses exhibit similar affinities for soluble CD4 (Brighty et
al., 1991; Moore et al., 1991). By contrast, binding of CD4
by the trimeric envelope glycoprotein complex of the TCLA
viruses is more efficient than that of the primary isolates
(Kabat et al., 1994; Moore et al., 1992; Platt et al., 1997).
A model of virus entry mediated by the HIV-1 envelope
glycoproteins has been deduced from the results of numer-
ous in vitro and in vivo investigations, including the crystal
structure of the CD4-bound gp120 core glycoprotein (re-
viewed in Wyatt and Sodroski, 1998). Initially gp120 binds
to the primary receptor, CD4, and undergoes a conforma-
tional change that allows a high-affinity interaction with the
chemokine receptor. The conformational change likely in-
volves movement of the large, disulfide-linked V1/V2 loop
and formation of a minidomain bridging sheet (Kwong,
1998, no. 4364; M. Koch and R. Wyatt, unpublished data).
The envelope glycoproteins of some HIV-1 variants that
have been adapted to replicate on CD4-negative target cells
are able to bind chemokine receptor in a CD4-independent
manner (Bandres et al., 1998; Kolchinsky et al., 1999). One
such gp120 glycoprotein achieves CD4 independence by
deleting a single N-linked glycan in the V1/V2 stem of the
exterior envelope glycoprotein (Kolchinsky et al., 1999).
The chemokine receptor-binding site minimally involves
elements of the V3 loop and residues within the C4 region
of gp120. Interaction of gp120 with coreceptor is believed
to trigger a second conformational change that allows in-
sertion of the hydrophobic amino-terminal fusion peptide of
the HIV-1 transmembrane protein, gp41, into the target cell
membrane (Bergeron et al., 1992; Gallaher, 1987). Thus,
gp41 bridges the viral and target cell membranes. Subse-
quent conformational rearrangement of this prefusogenic
intermediate into a lower energy state presumably brings the
two membranes into direct juxtaposition, allowing mem-
brane fusion to ensue (Chan et al., 1997; Chan and Kim,
1998; Tan et al., 1997; Wang et al., 1998; Weissenhorn et
al., 1997). Membrane fusion permits entry of the HIV-1
core into the cytoplasm of the target cell and initiates the
infection process.
The HIV-1 envelope glycoproteins have evolved a num-
ber of features that contribute to evasion of the host immune
response. In addition to the variability of some gp120 re-
gions, conformational flexibility and an extremely high de-
gree of carbohydrate may contribute to the masking of
functionally constrained gp120 elements (Kwong et al.,
2002c; Myszka et al., 2000; Wyatt and Sodroski, 1998).
More than half of the molecular weight of gp120 is due to
N-linked glycosylation. The extensive glycosylation of the
gp120 glycoprotein is likely to be involved in evasion of
host immune responses in at least two distinct ways. First,
the crystal structure of the gp120 core has revealed that
much of the glycosylation lies on the gp120 outer domain,
which is likely to be the region most exposed to the host
humoral immune system. This glycosylated surface likely
appears as “self” to the host immune system. Indeed, this
so-called “silent face” of gp120 seldom elicits antibodies
and thus appears to avoid the generation of potential neu-
tralizing humoral responses (Wyatt et al., 1998).
A second contribution of glycosylation may be to en-
hance the ability of the virus to resist envelope-directed,
antibody-mediated neutralization by the steric shielding of
potential neutralizing determinants with carbohydrate moi-
eties. Consistent with this hypothesis is the observation that
sensitivity of TCLA HIV-1 strains to neutralization by V3-
directed antibodies is influenced by glycosylation of the V3
loop (Back et al., 1994; Hansen et al., 1996; Schonning et
al., 1996b). Primary isolates are usually insensitive to neu-
tralization by most envelope glycoprotein-directed antibod-
ies (Sullivan et al., 1995) and glycosylation may play a role
in the resistant phenotype. Presumably, the glycosylation
contributes to neutralization resistance by direct steric in-
terference with antibody access to both strain-restricted and
more conserved neutralizing determinants. During the prep-
aration of this manuscript, Malenbaum et al. (2000) reported
that removal of the 301 glycan resulted in increased neu-
tralization sensitivity of HIV-1 to CD4 BS antibodies, in-
cluding some primary isolates. In addition, the two viruses
lacking the 301 glycan also demonstrated sensitivity to
CD4i antibodies. However, no direct studies on antibody
recognition of the viral “glycan types” were performed, so
the mechanistic basis for the observed changes remains
unclear.
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Other studies have implicated primate immunodeficiency
virus gp120 glycosylation in the evasion of host neutralizing
responses or in receptor interaction. In one study, the elim-
ination of N-linked glycosylation in the V1/V2 loop of
pathogenic SIV mac239 rendered the virus more sensitive to
host antibody responses (Reitter et al., 1998). Other work
has mapped the ability of the HIV-1 primary R5 isolate
ADA to achieve CD4 independence to a single sugar resi-
due in this same V1/V2 stem loop region (Kolchinsky et al.,
1999). The resulting CD4-independent R5 virus becomes
extremely sensitive to antibody-mediated neutralization
(Kolchinsky et al., 2001). Indeed, several studies have
shown that complete deletion of the V2 or V1/V2 regions,
and the several glycosylation sites present in these regions
increased sensitivity to antibody-mediated neutralization
(Cao et al., 1997; Stamatatos and Cheng-Mayer, 1998; Sta-
matatos et al., 1998). However, since both peptide and
sugars were eliminated in these studies, it was not possible
to assess the relative contribution of each modification to
neutralization sensitivity.
The crystal structure of the HIV-1 gp120 core glycopro-
tein has been solved in complex with CD4 and the CD4i
antibody 17b (Kwong et al., 1998, 2000a; Wyatt et al.,
1998). Subsequent studies based in part upon the observed
17b-gp120 contacts have determined that the 17b epitope
overlaps with the elements of the gp120 chemokine recep-
tor-binding site (Rizzuto et al., 1998). Thus, resolution of
both gp120 receptor-binding sites, analyzed in the context
of mutagenic mapping of gp120 antibody epitopes, has
allowed us to deduce that HIV-1 neutralizing antibodies are
often directed against receptor-binding regions. Thereby,
the CD4 binding site (CD4BS) antibodies recognize
epitopes near the CD4 binding region, whereas the CD4-
induced (CD4i) and V3 antibodies recognize epitopes im-
plicated in chemokine receptor binding (Wyatt et al., 1998).
The V3 loop, not present in the available crystal struc-
tures, also contributes to chemokine receptor interaction and
has been schematically modeled onto the gp120 core in the
context of a trimeric model of gp120 (Wyatt et al., 1998).
The enzymatically deglycosylated gp120 core in the X-ray
crystal structure retained the peptide-proximal N-acetylglu-
cosamine residues, which were resolved in the structure.
The mannose cores of these sugars have been computation-
ally modeled in the context of monomeric and trimeric
gp120 (Kwong et al., 2000b; Wyatt et al., 1998).
This structure-based analysis has allowed us to target
several N-glycans in close proximity to conserved receptor
binding sites that might potentially limit the access of neu-
tralizing antibodies to these functionally conserved regions
(Fig. 1). We examined the effects of these structure-based
glycan deletions on the neutralization sensitivity of primary
isolates by CD4BS and CD4i antibodies and a V3-loop
directed antibody. Compared with wild-type viruses, pri-
mary isolates lacking the N-glycan at residue 301 in the V3
loop were more sensitive to neutralization by CD4BS anti-
bodies and a V3 loop-directed antibody, but not to CD4i
antibodies. Increased antibody recognition of the envelope
glycoproteins lacking the 301 glycan was observed, indicat-
ing a potential mechanism of immune evasion. In contrast to
the isolates examined in the Mallenbaum study, we report
that only in the absence of four N-glycans proximal to
receptor binding regions did the primary isolate examined in
our study become sensitive to CD4i antibodies.
Results
Selection of N-linked glycosylation sites for modification
Primary isolates of HIV-1, including the R5 viruses
JR-FL and YU2 used in this study, are relatively resistant to
most CD4BS antibodies; the one exception is the CD4BS
antibody IgGb12 (Burton et al., 1994; Roben et al., 1994;
Sullivan et al., 1995). Even in the case of the more potent
IgGb12 antibody, primary isolates are more resistant to
neutralization when compared to TCLA viruses (Sullivan et
al., 1995). Many primary HIV-1 isolates have also been
shown to exhibit a decreased sensitivity to sCD4 neutral-
ization relative to that of TCLA viruses (Sullivan et al.,
1995). We sought to examine the sensitivity to neutraliza-
tion by several CD4BS and CD4i monoclonal antibodies
and sCD4 of primary viruses with envelope glycoproteins
lacking specific N-linked glycosylation sites. The decision
of which glycosylation sites to eliminate was based upon
molecular modeling of the HXBc2 gp120 core crystal struc-
ture (Kwong et al., 1998). The validity of this model for
primary isolates has subsequently been demonstrated by the
crystal structure of the gp120 core of the clinical HIV-1
isolate, YU2 (Kwong et al., 2000a). In the solved crystal
structures, many of the peptide-proximal N-acetylglu-
cosamine residues were retained. The mannose core moi-
eties were then modeled onto this gp120 core structure as
previously described (Kwong et al., 1998; Wyatt et al.,
1998). Inspection of this model led to the observation that
sugar moieties at asparagines 197 and 276 were proximal to
the CD4 binding site (Fig. 1, top). Carbohydrate residues at
asparagines 301 and 386 were in relatively close proximity
to the putative chemokine receptor-binding site (Fig. 1,
bottom). Therefore, we eliminated these glycosylation sites
both singly and in combination in the HXBc2 virus. The
carbohydrate addition site at asparagine 197 in the HXBc2
isolate is not present in the JR-FL strain and so only the
glycosylation sites at 276, 301, and 386 were removed from
the envelope glycoproteins of this virus. For the YU2 virus
we eliminated the glycan at residue 301.
Antibody recognition of monomeric gp120 and replicative
ability of gp120 glycosylation mutants
Soluble, monomeric HXBc2 and JR-FL gp120 molecules
with the sugar deletions were analyzed for recognition by
several CD4BS antibodies and CD4i antibodies, by soluble
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CD4 and by a mixture of sera from HIV-1-infected individ-
uals in immunoprecipitation assays. No significant differ-
ences in ligand recognition between the glycan-deleted
gp120 glycoproteins and wild-type glycoproteins were ob-
served (data not shown).
To assess the effect of the sugar deletions in the context
of the functional envelope oligomer, recombinant virions
with the wild-type and carbohydrate-deleted envelope gly-
coproteins were produced in 293T cells. Infectivity of vi-
ruses with the YU2 and JR-FL 301 envelope glycoproteins
was similar to that of viruses with the respective wild-type
envelope glycoproteins (data not shown). Viruses with the
JR-FL 276/301/386 envelope glycoproteins infected target
cells at roughly 10% the efficiency of the viruses with the
Fig. 1. Top: on the left is shown the molecular surface of the gp120 core in red with the CD4 contacts shown in yellow. In this orientation, the viral cell
membrane would be at the top of the page and the target cell membrane would be toward the bottom of the page. To the right is the -carbon chain of the
gp120 core (in red) shown in the same orientation. The NMR V3 loop structure has been modeled on to the gp120 core as previously described and is shown
in brown (Kwong et al., 2000b). The molecular surface of the mannose cores of the four targeted glycans at residues 197, 276, 301, and 386 previously
modeled in the Kwong study are shown in blue. The molecules of the other gp120 sugars previously modeled are shown in green. Bottom: on the left is shown
the molecular surface of the core gp120 glycoprotein rotated 90° relative to the top and viewed from the perspective of the target cell. The protruding V1/V2
stem projects toward the top of the page. The gp120 core residues implicated in CCR5 binding are shown in cyan, while the remaining surface residues are
colored in red. The CD4 binding site is located on the plane of the molecule that projects into the page and is marked with an arrow. To the right is the
-carbon chain of the gp120 core in the same orientation, the sugars colored as described above. As can be seen in the model, the glycans at asparagines
301 and 386 lie most proximal to the residues implicated in chemokine receptor binding.
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respective wild-type envelope glycoproteins (data not
shown). The lower level of infectivity may be, in part, due
to a slight increase in shedding of gp120 from the envelope
glycoprotein complex, which was observable in 293T cells
transiently transfected with the JR-FL 276/301/386 enve-
lope glycoprotein expressor plasmids and analyzed by im-
munoprecipitation (data not shown). Nevertheless, the vi-
ruses with the JR-FL 276/301/386 envelope glycoproteins
were able to infect target cells at a significant and repro-
ducible level. HXBc2 197/276/301/386 viruses infected
CXCR4-expressing target cells at a level that was too low to
generate reproducible entry and neutralization data (not
shown).
Neutralization sensitivity of glycosylation mutants
To determine effects of the sugar deletions on neutral-
ization sensitivity, viruses were incubated with selected
antibodies or sCD4, prior to the addition to either CD4/
CCR5 or CD4/CXCR4 Cf2Th target cells. Viruses with
the JR-FL and YU2 301 envelope glycoproteins were
tested for neutralization sensitivity by selected CD4BS an-
tibodies, IgGb12, F105, 15e, and 21h and by the V3 loop-
directed antibody 39F. Of the set of CD4BS antibodies,
IgGb12 alone had been shown to neutralize the wild-type
JR-FL or YU2 viruses (Moore et al., 1995; Roben et al.,
1994; Sullivan et al., 1995).
As anticipated, in this study IgGb12 was the sole CD4BS
antibody able to inhibit the entry of recombinant viruses
with the wild-type JR-FL envelope glycoproteins (Table 1).
However, in contrast to wild-type JR-FL viruses, viruses
containing the JR-FL 301 envelope glycoproteins were
sensitive to neutralization by all of the CD4BS antibodies
tested. In addition, viruses with the JR-FL 301 envelope
glycoproteins were three-fold more sensitive to IgGb12
neutralization, compared to viruses with the wild-type
JR-FL envelope glycoproteins (Table 1).
Similar effects were observed for viruses containing the
mutant envelope glycoproteins of the primary isolate YU2.
In the presence of the 15e or 21h CD4BS antibodies, the
entry of viruses with the YU2 301 envelope glycoproteins
was inhibited by nearly 50% under the conditions tested
(Fig. 2 and Table 1). This effect was significantly different
from that observed for viruses containing the wild-type
YU2 envelope glycoproteins, which were not neutralized
under the test conditions. In fact, the viruses with the wild-
type YU2 envelope glycoproteins were not only resistant to
neutralization by the 15e and 21h antibodies, but demon-
strated enhanced entry in the presence of these antibodies
(Fig. 2 and Table 1), consistent with previous studies (Sul-
livan et al., 1998). The YU2 wild-type virus was resistant to
the V3 loop-directed antibody 39F, whereas the 301 virus
was rendered sensitive to 39F-mediated neutralization by
removal of the 301 glycan (Fig. 2).
Increased sensitivity of viruses with envelope glycopro-
teins lacking the N-glycan at residue 301 to neutralization
by CD4BS antibodies was not restricted to primary isolates,
but was also observed for TCLA viruses possessing HXBc2
Table 1
The concentration of antibody or sCD4 (g/ml) required to neutralize 50% of the infection of recombinant HIV-1 with the indicated envelope
glycoprotein is shown
Envelope
glycoprotein
strain
Envelope
glycoprotein
variants
Ligands
CD4BS CD4i  gp41
F105 IgGb12 15e 21h 17b 48d 2F5 sCD4
JR-FL Wild-type 50 0.05     0.7 1.0
276 50 0.05 ND ND   ND 0.5
301 1.0 0.017 0.7 10.8   0.7 0.12
386 50 0.04 ND ND   ND 2.0
301/386 3.0 0.01 ND ND   ND 0.21
276/301/386 0.4 0.007 ND ND 10 0.6 0.6 0.18
YU2 Wild-type  2.3   ND ND 3.0 0.35
301 9.0 0.2 41.0 32.0 2.8 0.024
HXBc2a Wild-type 1.1 0.029 3.0 44 ND ND ND ND
197 0.4 0.01 ND ND
276 0.2 0.028 ND ND
301 0.026 0.01 0.01 0.01
386 0.2 0.032 ND ND
301/386 0.036 0.007 ND ND
Note. Entry of viruses containing envelope glycoprotein variants from the HXBc2 strain was determined using CXCR4 and CD4 expressing Cf2Th cells
as target cells while entry of viruses with YU2 or JR-FL envelope glycoproteins was determined using CCR5 and CD4 expressing Cf2Th cells as target cells.
It is not possible to quantitatively compare the activity of inhibitory ligands between viruses that enter different target cells. 50, Greater than all
concentrations tested; previous studies report neutralization by this ligand at higher concentrations., Greater than all concentrations tested; previous studies
report neutralization resistance to this ligand. ND, not determined.
a HXBc2 197/276/301/386 viruses (similar to the JR-FL 276/301/386 viruses, which naturally lack the 197 glycan) infected CXCR4-expressing target
cells at a level that was too low to generate reproducible entry and neutralization data.
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envelope glycoproteins. The viruses with the HXBc2 301
envelope glycoproteins were 30- to 40-fold more sensitive
to neutralization by F105, 15e, and IgGb12 compared to
viruses with the wild-type HXBc2 envelope glycoproteins.
These data support previous reports that have shown greater
neutralization sensitivity of TCLA viruses lacking the 301
glycosylation site for both V3 loop antibodies and one
CD4BS antibody (Back et al., 1994; Schonning et al.,
1996b).
Viruses with envelope glycoproteins lacking the N-gly-
can at position 301 were also more sensitive to neutraliza-
tion by sCD4 (Table 1). The viruses with the JR-FL 301
envelope glycoproteins were fivefold more sensitive than
viruses with the wild-type JR-FL envelope glycoproteins.
An even greater effect was observed for the viruses con-
taining the YU2 301 glycan envelope glycoproteins. Here
a 10-fold increase in sensitivity to neutralization by sCD4
was observed relative to viruses with the wild-type YU2
envelope glycoproteins (Fig. 2 and Table 1).
The individual removal of N-glycans from asparagines
276 and 386 did not affect the sensitivity of viruses with
these envelope glycoproteins to neutralization by the anti-
bodies tested. However, viruses with envelope glycopro-
teins lacking N-glycans at three residues (asparagines 276,
301, 386) were more sensitive to neutralization by a range
of antibodies. Viruses with JR-FL envelope glycoproteins
lacking the glycosylation sites at 276, 301, and 386 were not
only more sensitive to CD4BS antibodies and sCD4, pre-
sumably due to the missing N-glycan at residue 301, but
were also more sensitive to the two examined CD4i anti-
bodies, 17b and 48d (Fig. 3 and Table 1). These antibodies
are relatively ineffective at neutralizing primary HIV-1 iso-
lates, even at the highest concentrations tested (Sullivan et
al., 1998; Thali et al., 1992). Even for TCLA HIV-1 viruses,
more than 30 g/ml of 17b was reported to be required to
achieve 90% inhibition of a representative isolate (Thali et
al., 1993). In this study, 17b and 48d were able to neutralize
viruses with the JR-FL 276/301/386 envelope glycopro-
teins with IC50s of 10 and 0.6 g/ml, respectively (Fig. 3).
To examine if viruses with envelope glycoproteins lack-
ing the three N-glycans were generally sensitive to anti-
body-mediated neutralization, we examined the sensitivity
of these viruses to neutralization by 2F5, an antibody di-
rected against a gp41 epitope. No difference was observed
Fig. 2. Neutralization curves of wild-type YU2 luciferase viruses () and 301YU2 luciferase viruses (F) with the CDBS antibodies IgGb12, F105, and 15e,
the V3 loop antibody 39F, soluble CD4, and the gp41 antibody 2F5. Values are presented as percentage luciferase activity and are normalized to 100% virus
entry into Cf2Th target cells in the absence of any ligand. The data points presented represent the average of three independent experiments (39F two
experiments) with the error bars representing the standard deviation between these experiments.
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in the sensitivity to 2F5 neutralization of viruses lacking
N-glycans when compared to viruses with wild-type enve-
lope glycoproteins (Figs. 2 and 3 and Table 1).
Antibody binding to cells expressing envelope
glycoprotein
To determine if a higher level of antibody binding to
oligomeric envelope glycoproteins derived from the neu-
tralization-sensitive 301 glycan JR-FL virus, as opposed
to the neutralization-resistant wild-type JR-FL viruses,
could be observed, quantitative cell-surface staining was
performed. Equivalent levels of cell-surface expression of
the two JR-FL oligomers (wild-type and 301 glycan) were
confirmed by cell-surface staining using a pool of IgG
proteins from HIV patients (HIVIgG) and the 2F5 antibody
(Fig. 4), which neutralized both viruses equivalently (Fig. 4
and Table 1). In some experiments, staining with the 2G12
antibody was also included to assess equivalent expression
of the two glycoproteins (representative data shown in Fig. 4).
The IgGb12 antibody bound to both the wild-type and
the 301 oligomeric glycoproteins at significant levels in a
dose-dependent manner (Fig. 4). In the experiment shown,
for both envelope glycoproteins, saturation binding of b12
was achieved at 10 g/ml and half-maximal binding at less
than 1 g/ml. Saturation binding of b12 at these concentra-
tions was observable in all experiments (n  5). The V3
loop-directed antibody 39F, which could neutralize the YU2
301 virus but not wild-type virus, bound the 301 oligo-
meric glycoproteins approximately fourfold better at 100
g/ml (10 g/well; Fig. 4). Saturation binding of 39F was
not achieved to the 301 glycoproteins at the highest anti-
body concentrations tested, so this significantly increased
binding may be an underestimate of differential recognition
by 39F of the two glycoproteins. The F105 antibody also
bound the envelope glycoproteins derived from F105-sen-
sitive 301 JR-FL virus at a higher level (nearly threefold
greater binding at 100 g/ml) than the glycoproteins de-
rived from the F105 neutralization-resistant wild-type
JR-FL isolate (Fig. 4). The level of F105 staining, as well as
that of 2F5, was significantly lower than that of IgGb12 to
either wild-type or 301 glycoproteins or that of 39F to the
301 glycoproteins (Fig. 4).
Although the observed staining of F105 and 2F5 to wild-
type oligomers was at a low level, it increased with increasing
antibody concentrations and was significantly different from
negative controls. When we used an anti-RSV human IgG1
antibody as a negative control, a much lower level of back-
ground staining was observed. The level of the anti-RSV
staining remained below 10 mean fluorescence intensity (MFI)
units up to concentrations of 250 g/ml (Fig. 4 and data not
shown). For F105, 2F5, and the V3 loop antibody 39F, binding
to the wild-type oligomers did not achieve saturation (Fig. 4).
To accurately assess half-maximal binding levels of these
antibodies as compared to the levels of IgGb12 and 2G12, it is
necessary that each antibody achieve saturation binding. Pre-
sumably this is due to full-site occupancy of each particular
epitope. The IgGb12 antibody achieved saturation binding to
wild-type oligomers at 10 g/ml and half-maximal binding at
less than 1 g/ml, but F105 continues to increase its binding as
the antibody concentration is increased (Fig. 4). Even at 100
g, the highest level of F105 antibody, the F105 achieves an
MFI of 40, fivefold less than that of the binding that IgGb12
achieves (and maintains) at a 10-fold lower dosage (200
MFI, Fig. 4). Therefore this large difference in the level of
binding achieved by the two antibodies, while only an under-
estimate of the actual binding differences, is consistent with the
distinct neutralizing properties of the antibodies.
Discussion
Due to its location on the surface of the virus, HIV-1
gp120 is the major target for neutralizing antibodies. The
extreme degree of gp120 glycosylation has led to the fre-
quent suggestion that this extensive carbohydrate content
Fig. 3. Neutralization curves of JR-FL wild-type and selected glycan-deleted luciferase viruses by the CD4i antibodies 17b and 48d presented as percentage
luciferase activity normalized to 100% entry of each virus into Cf2Th target cells in the absence of antibody. The symbols represent the following viruses:
JR-FL wild-type (, containing a natural 197 glycan deletion); 301 JR-FL (F); 276 JR-FL (‚); 386 JR-FL ({); 301/386 JR-FL (Œ), and 276/301/386
JR-FL (}). The data points presented represent the average of three independent experiments with the error bars representing the standard deviation between
these experiments.
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may contribute to escape from immune selective forces
imposed by neutralizing antibodies (Cheng-Mayer et al.,
1999; Moore et al., 1995; Olofsson and Hansen, 1998;
Reitter et al., 1998; Roben et al., 1994; Schonning et al.,
1996a). The solution of the gp120 core crystal structure has
afforded testable hypotheses in this regard. In this study, we
sought to determine if removal of specific sugars proximal
to receptor-binding regions would affect the neutralizability
of HIV-1 or recognition by HIV-1 monoclonal antibodies.
We observed two distinct effects of targeted gp120 sugar
removal on the neutralization sensitivity of primary HIV-1
isolates. The first and major effect was that removal of an
N-linked glycosylation site at the base of the V3 loop
rendered two primary viruses significantly more sensitive to
neutralization by a panel of CD4BS antibodies as well as to
neutralization by sCD4 and a V3 loop-directed antibody.
These observations are in agreement with previous reports
demonstrating that removal of the 301 glycan in two TCLA
viruses and two primary isolates increased their sensitivity
to inhibition by CD4BS antibodies (Back et al., 1994;
Malenbaum et al., 2000). The second effect that was ob-
served in our study was an increase in HIV-1 sensitivity to
the CD4i antibodies 17b and 48d.
These observations then lead to the question of mecha-
nism: does the removal of the 301 glycan remove a steric (or
conformational) blockade and allow access to neutralizing
determinants not accessible on the wild-type oligomer? We
have addressed this issue by performing FACS-based bind-
ing assays. To date it has been difficult to demonstrate a
correlation between antibody recognition and neutralization
sensitivity/resistance of primary isolates. This has been ac-
complished for lab-adapted strains (Sattentau and Moore,
1995) and more recently for SHIV-derived Envs (Si et al.,
2001) and for one primary isolate (Fouts et al., 1997). Using
a method similar to Si et al., we have studied antibody
binding to envelope glycoproteins expressed on the cell
surface of transfected cells to generate binding curves that
allow a relative binding comparison and, for some antibod-
ies where saturation binding is achieved, an affinity esti-
mate.
These data reveal several observations relevant to anti-
body recognition of oligomeric Env. A rank order of bind-
Fig. 4. FACs-based binding curves to JR-FL cleavage-competent wild type envelope glycoproteins () and 301 glycan proteins () expressed on the surface
of transiently transfected 293T cells with the anti-HIV-1 human antibodies, 2G12, HIVIgG, IgGb12, F105, 39F, 2F5, and the negative control human IgG1
antibody, Anti-RSV. The data shown are from a representative experiment performed with duplicate samples with the exception of the 2G12 and anti-RSV,
which are from an independent but similar experiment. Error bars indicate the range of values obtained for duplicate samples. The analysis of IgGb12, F105,
39F, and 2F5 were repeated in five independent experiments and the staining with 2G12, anti-RSV, and HIVIgG were repeated three times with similar
results.
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ing to wild-type JR-FL oligomers by the gp120-directed
antibodies, as determined by MFI levels at increasing anti-
body concentrations, is 2G12  b12  39F, F105. Since
the data correlate with neutralization sensitivity, they sug-
gest that both 2G12 and b12 can achieve higher levels of
site occupancy than the less potent gp120-directed neutral-
izing antibodies. That the potent, gp41-directed antibody
2F5, which binds at relatively low levels, does not fit this
general pattern may reflect a distinct mechanism of neutral-
ization for this antibody. Perhaps lower site occupancy of its
epitope is still sufficient to achieve neutralization by inter-
fering with the fusion process in a manner yet to be defined.
The same rank order is observable on 301 oligomeric
glycoproteins, except that (a) 39F binding now approaches
b12 MFI at the highest concentrations tested (but does not
fully saturate) and (b) F105 binds at a slightly but repro-
ducibly higher level compared to wild-type JR-FL Env and
also does not achieve saturation binding (five independent
experiments). Because F105 does not achieve saturation, an
accurate quantitative comparison between F105 and b12
binding is not possible. The general trend that higher levels
of binding correlate with increased potency of gp120-di-
rected antibody neutralization is consistent with these ob-
servations. This again suggests that an increased degree of
“site occupancy” is required to achieve neutralization for
the gp120 epitopes. By site occupancy we mean either a
greater number of antibody binding events per oligomer or
a greater number of oligomers recognized on either the cell
surface or the virus. A spike occupancy model does not
reconcile the data in its entirety since F105 does not closely
achieve MFI levels of b12 or 2G12 under the conditions
tested, yet is still able to neutralize the 301 virus. Perhaps
this reflects differences in binding kinetics, potency, or
mechanisms of neutralization for each antibody or epitope.
How might the available information on HIV-1 gp120
structure explain the observed increase in neutralization
sensitivity of the virus and increased antibody recognition
engendered by deletions of the V3 loop glycan at asparagine
301? That the V3 loop is capable of conformational rear-
rangement is consistent with the observation that the V3
loop becomes more sensitive to proteases following CD4
binding (Sattentau and Moore, 1991). A previous study on
the lab-adapted isolate BRU-2 showed that BRU 301
oligomeric glycoproteins, but not monomers, were better
recognized by a V3 loop antibody than wild-type BRU
oligomers (Schonning et al., 1996b). In a structural context,
these results can be viewed in at least two ways: potential
effects confined to interactions within a single monomeric
gp120 subunit or potential effects occurring between adja-
cent monomers within the context of a functional trimer.
Within the gp120 monomer, both direct and indirect
effects are possible. For purposes of interpreting the data,
we have utilized the previously described model in which an
NMR-derived V3 loop structure was affixed to the CD4-
bound gp120 core crystal structure (Kwong et al., 2000b
and Fig. 4). Because this is a model, there is uncertainty in
defining both the orientation and the conformation of the V3
loop and assigning the orientation of the V3 loop 301
glycan. Despite this caveat, direct effects of modification of
glycan 301 on the CD4 binding site itself appear unlikely
based upon the trimeric model derived from the known
structures. In this model, the V3 loop resides on the “bot-
tom” of the envelope spike and the 301 glycosylation site is
relatively close to the disulfide-linked V3 base (Kwong et
al., 2000b). For the V3 loop to reposition proximal to the
CD4 binding site would require an unlikely and extensive
rotational movement of the outer domain relative to the
inner domain. That there was no effect of removing 301
N-linked glycosylation on CD4 binding site antibody rec-
ognition in the context of monomeric gp120 (data not
shown) supports the notion that 301 glycosylation removal
does not exert a direct effect on exposure of the CD4
binding site. However, these observations should be inter-
preted with some caution for the following reasons. Al-
though immunoprecipitation experiments did not reveal any
difference in antibody recognition of monomeric gp120
with or without the targeted sugars, such effects may not be
readily apparent within the context of the free monomer.
Thermodynamic analysis indicates that monomeric gp120 is
extremely flexible and exhibits considerable entropy that is
greatly reduced upon binding of gp120 to CD4 (Myszka et
al., 2000). Due to these properties, the assessment of some
structural relationships by antibody binding analysis may
not be easily achieved in the context of monomeric gp120.
The flexibility of gp120 may allow a ligand to reposition
proximal gp120 elements without observable steric hin-
drance. However, in the oligomeric context, the individual
monomers are likely more constrained in conformation.
Thereby, although the structural proximity of two elements
within a gp120 monomer may be more or less the same,
steric hindrance will be more manifest in the context of the
oligomer. With this cautious note in mind, it is possible that
deletion of carbohydrate at residue 301 repositions the
V1/V2 region, or some other gp120 element, within the
same monomer and increases neutralization sensitivity in an
indirect manner.
Another interpretation of these data is suggested by the
trimeric gp120 model previously described (Kwong et al.,
2000b). This model is based upon the optimization of quan-
tifiable surface parameters of the gp120 monomeric core
crystal structure to create a trimer. Three different V3 loop
models were then constructed using steric hindrance as the
only constraint. Each of these models suggests that the V3
base of one monomer is located in close proximity to the
V1/V2 stem of an adjacent monomer (Kwong et al., 2000b
and Fig. 5). Therefore, removal of the sugar on asparagine
301 in the base of the V3 loop might allow a repositioning
of the V1/V2 stem on the adjacent monomer. In this inter-
pretation, the V1/V2 loop itself or some other element of
gp120 influenced by the stem rearrangement now becomes
less effective at sterically shielding the CD4 binding site
(see Fig. 5). If this conjecture were valid, then one would
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expect that the effects of the removal of carbohydrate at
position 301 on antibody accessibility to the CD4 binding
site would be observed only in the context of the oligomer.
The interpretation is consistent with the data presented here.
Yet another potential explanation of the data is that many
or most CD4BS antibodies bind gp120 with an orientation
that results in much of the antibody mass being positioned
between the viral envelope glycoproteins and the target cell.
This might be the case even if the antibody epitope itself is
located on the side of the viral spike overlapping the CD4
binding site. Removal of the sugar moieties at position 301
in the base of the V3 loop would better allow such an
orientation by removing a steric hindrance. This orientation
of some CD4BS antibodies might allow these antibodies to
interfere with both CD4 binding and chemokine receptor
interaction. Indeed, antibody competition analyses have re-
vealed that CD4BS antibodies compete with sCD4 and
antibodies directed against the chemokine receptor-binding
surface of gp120 (Moore and Sodroski, 1996). Data recently
obtained with CD4-independent HIV-1 isolates supports the
Fig. 5. A trimeric model of the gp120 core glycoprotein shown from the perspective of the target cell (same as in Fig. 1, bottom) is based upon quantifiable
surface parameters as previously described (Kwong et al., 2000b). The -carbon chain of the gp120 core is shown in red and the V3 loop -carbon chain
is in brown. The molecular surfaces of the targeted glycans are shown in blue and labeled on one gp120 monomer. The proximity of the 301 glycan to the
V1/V2 stem and 197 glycan on an adjacent monomer is apparent. The other sugar molecules are colored green. The CD4 binding site is labeled (CD4) and
marked with an arrow on one gp120 monomer.
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notion that CD4BS antibodies interfere with CCR5 binding
(Raja et al., 2003).
If the carbohydrate at position 301 in the V3 loop was
positioned proximal to the chemokine receptor-binding site
in the CD4-free state, one might expect that deletion of this
sugar might affect chemokine receptor binding. Enhance-
ment of chemokine receptor binding by 301 glycan removal
has been reported (Malenbaum et al., 2000), although this
was not observed in another study (Losman et al., 1999).
Another prediction might be an increase in 17b neutralizing
capacity, since this epitope overlaps the chemokine recep-
tor-binding site and the neutralization capacity of 17b is
increased by subneutralizing concentrations of sCD4 (Sul-
livan et al., 1998). In the Malenbaum study, the viruses
lacking the 301 glycan described did become more neutral-
ization sensitive to three CD4i antibodies. However, for the
isolates used in our study, 301 glycan deletion did not
enhance CD4i antibody-mediated neutralization and the
JR-FL isolate, already lacking the glycan at 197, required
the additional deletion of glycans at positions 276 and 386
to achieve sensitivity to CD4i antibody neutralization. Here,
the absence of these sugars resulted in no apparent increase
in 17b recognition of monomeric gp120, indicating that the
effects of sugar removal are manifest only in the context of
the oligomeric spike. Further structural studies of oligo-
meric HIV envelope glycoproteins should clarify the role of
these sugars in occluding the 17b epitope in the context of
the functional oligomer.
Although we cannot explain all of the data in a precise
structural manner, a general pattern emerges consistent with
the following scenario. Selective pressures drive the evolu-
tion of viral spikes that best maintain a contiguous steric
barrier or “protective shell” composed of sugars and vari-
able loops. Presumably these barriers are required to ob-
scure functionally conserved regions from potentially neu-
tralizing antibodies, consistent with the recently proposed
evolving glycan shield mechanism (Wei et al., 2003). For
the more broadly neutralizing CD4BS antibodies, the re-
moval of a single sugar at the base of the V3 loop, either
indirectly or directly, allows these antibodies to access the
CD4 binding site and neutralize primary HIV-1 isolates.
This is consistent with the correlation to neutralization we
observed in our binding studies: the more potent gp120
antibodies bound to a greater extent and all gp120 neutral-
izing antibodies bound 301-glycan-deleted oligomers more
efficiently than wild-type oligomers. For the viruses studied
here, the CD4i antibodies require larger “holes” in this
protective shell, provided by removal of the three glycans,
to access their epitopes and neutralize virus. Previously, we
have shown that the removal of a single N-linked carbohy-
drate in the V1/V2 stem of the primary ADA HIV-1 isolate
results in CD4 independence and increased neutralization
sensitivity (Kolchinsky et al., 2001a, 2001b). In this case,
the phenotypes associated with the presence or absence of
the carbohydrate were dependent on the integrity of the
V1/V2 variable loops. Thus, even a single sugar can exert
major effects on the positions of large variable loops in the
context of either monomeric or trimeric envelope glyco-
proteins.
Removal of the 301 glycan could involve rearrangement
with both the same monomer and the adjacent monomer. In
this sense, a trimer from a given HIV-1 strain can be viewed
as a unique “jig-saw puzzle” that has been selected to
achieve a proper “fit” by functional constraints and by host
immune selection pressures. Particular perturbations of this
specific fit can cause rearrangements of trimeric elements
and alter exposure of normally concealed determinants.
Effects of some of these perturbations may be strain-specific
if they, for example, involve variable region interfaces.
Others, such as removal of the 301 glycan and exposure of
the CD4 binding site, may exert effects on multiple enve-
lope strains if they are involved in common mechanisms
used to maintain trimeric spike fitness, although some
HIV-1 isolates retain function and neutralization resistance
even in the absence of the N-glycan at asparagine 301. The
dynamic process of mutational selection leads to a myriad
of strain-specific envelope structures that are unique in their
subtle variations within the boundaries aforementioned: mu-
tation, compensation, maintenance of envelope function,
and survival of the fittest viral forms selected by this pro-
cess. Further studies of the HIV envelope glycoproteins will
likely reveal the molecular details of this dynamic process.
The structural details of glycan-mediated neutralization re-
sistance/sensitivity and masking/exposure of neutralizing
determinants are important considerations for the selection
of particular envelope glycoproteins as subunit vaccine can-
didates.
Materials and methods
Plasmids
The plasmid pSVIIIenv, expressing the HIV-1 envelope
glycoproteins from the HXBc2, JR-FL, or YU2 isolate, has
been described previously (Helseth et al., 1990). For produc-
tion of viruses that contain mutant or wild-type envelope gly-
coproteins and express luciferase upon infection, the plasmid
pSVIIIenv was cotransfected with pCMVP1envpA and
pHIvcc2.luc. The plasmid pHIvec2.luc is derived from
pHIvec2.gfp that was supplied by Wolfgang Hofmann, Dana-
Farber Cancer Institute (Hofmann et al., 1999). It contains the
two exons of tat and the luciferase gene in an HIV-1 proviral
vector. The gag, pol, and env genes and the genes for the
accessory proteins are either deleted in total or are rendered
nonfunctional by partial deletion of coding sequences. The
luciferase gene was “excised” from the plasmid pGL3b (Pro-
mega, Madison, WI) using the restriction sites BglII and XbaI.
The luciferase gene was then inserted in place of the gfp gene
normally contained in the pHIvec2.gfp using the restriction
sites BamHI (3830) and XbaI (5535). The plasmid
pCMVP1envpA contains the functional HIV-1 gag and pol
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genes under the control of the CMV promoter. This plasmid
also contains the functional genes encoding the accessory pro-
teins Vif and Tat, whereas both the env and the nef genes are
deleted. Due to the deleted packaging signal (psi) in this
construct, the gag/pol messages are not incorporated into a
budding virion, eliminating the possibility of further rounds of
viral replication.
Mutagenesis
The glycosylation sites (NX(T/S)) at residues 276, 301,
and 386 were deleted in the JR-FL and HXBc2 envelope
glycoproteins by genetic mutation. The glycosylation site at
residue 301 in the YU2 envelope glycoprotein was deleted.
To achieve these alterations, either the sequence coding for
N was changed to code for Q (at residue 301) or the
sequence for T was changed to code for L or A (at residues
386 and 276). Amino acid substitutions were guided by
changes found in primate immunodeficiency viruses pos-
sessing envelope glycoproteins that lack those particular
glycosylation sites and thus naturally harbored the same
changes. Amino acid changes were introduced by site-di-
rected mutagenesis, utilizing a combination of the
QuikChange (Stratagene) and megaprimer protocols
(Brons-Poulsen et al., 1998). Briefly, the env gene was PCR
amplified using a 5 forward oligonucleotide harboring the
desired mutagenic changes (and as well, possessing a
unique restriction site) and a 3 reverse oligonucleotide
complementary to the wild-type env sequences. The PCR
product containing the desired mutant sequence was then
purified on an agarose gel and isolated from the gel by spin
columns (Qiagen). The isolated set of complementary oli-
gonucleotides was then utilized as a megaprimer pair to
perform QuickChange site-directed mutagenesis. The suc-
cessful deletion of the particular glycosylation site was
confirmed by restriction enzyme analysis and sequencing.
Neutralization assays
Complementation of a single round of replication of the
env-deficient luciferase-expressing proviruses by the vari-
ous envelope glycoproteins was performed as described
previously (Hofmann et al., 1999; Kolchinsky et al., 2001b).
To inhibit viral replication, monoclonal antibodies were
incubated with recombinant virus for 1 h at 37°C in DMEM
containing 10% heat-inactivated fetal bovine serum. Vi-
ruses and antibody were then added to Cf2Th target cells
expressing CD4 and CCR5 or CD4 and CXCR4. Three days
after infection, the cells were lysed with passive lysis buffer
(Promega), and luciferase activity was measured as relative
luminescence. The data shown are the arithmetical averages
of at least five independent experiments with the exception
of neutralization experiments using the 39F anti-V3 loop
antibody, which were performed twice.
Fluorescence activated cell sorting (FACS)
Cell-surface, FACS-based binding curves with antibod-
ies were generated as follows. 293T cells transiently ex-
pressing JR-FL gp160 glycoproteins or JR-FL 301 glycan
glycoproteins were stained and analyzed by FACS. Initially,
the cells were plated onto 150-mm tissue culture dishes at a
density of 10  106/plate. The following day the cells were
transfected with the pSVIIIenv expressor plasmids and
pSVIIItat using Fugene6 as per the manufacturer’s instruc-
tions (Roche; 5–10 g plasmid DNA/106 cells, DNA/Fu-
gene6 mass ratio 1/3). The JR-FL cleavage-competent gly-
coproteins contained stop codons in sequences encoding the
cytoplasmic tails to enhance cell-surface expression of the
oligomeric glycoproteins (at codon position 712, HXBc2
numbering). Forty-eight hours following transfection, the
cells were removed from the tissue culture dish using PBS
containing 5 mM EDTA, washed with FACS buffer (PBS
with 5% FCS and 0.02% azide) to remove the EDTA,
resuspended in FACS buffer, and dispensed into 96-well
microtiter flat-bottom plates at 106 cells/well. Antibodies
were added to the wells at 0 to 200 g/ml (HIVIgG to 2
mg/ml) in volume of 100 l/well and incubated for 1 h at
room temperature. For each antibody tested, duplicate wells
were done. The cells were washed extensively in FACS
buffer and a 1:150 dilution of anti-human IgG-R-Phyco-
erythrin (Sigma) in FACS buffer was added to all wells for
1 h at room temperature. The cells were then washed ex-
tensively in FACS buffer, fixed in 2% paraformaldehyde,
and analyzed on a FACS Calibur from Becton–Dickinson.
We have reported the data as the MFI of the total cells. The
data shown in Fig. 4 are from a single representative ex-
periment with the exception of the 2G12 and anti-RSV. The
FACS analysis of IgGb12, F105, 39F, and 2F5 was repeated
in at least five independent experiments and the staining
with 2G12, anti-respiratory syncytial virus (anti-RSV; neg-
ative control human IgG1, Medimmune), and HIVIgG were
repeated three times, with similar results.
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